Novel Micra Pacemaker Found to Reduce Patient Risk
A pragmatic comparative effectiveness study comparing Micra leadless pacemakers to conventional transvenous pacemakers found that for patients who received the novel leadless pacemakers, complicati
Oral Anticoagulation May Be Harmful to Patients with End-Stage Renal Disease
Oral anticoagulation (OAC), a treatment strategy commonly used to prevent stroke in patients with atrial fibrillation, may be harmful for patients with atrial fibrillation and end-stage renal disease, according to a recent study led by the DCRI. The study, which was led by the DCRI’s Sean Pokorney, MD, MBA, and published in Journal of the American College of Cardiology, used Medicare claims data to analyze a cohort of over 8,000 patients with both atrial fibrillation and end-stage renal disease.
Contributors to Inaccurate Heart Rate Measurements in Wearable Devices
A study led by DCRI and Duke researchers was the first to comprehensively explore skin tone as a potential factor affecting accuracy of heart rate measurements from wearable devices.
DCRI Study Examines Risk of Patients with Advanced Heart Failure Who Receive Defibrillators
When compared to patients with non-advanced heart failure, patients with advanced heart failure had a more than three-fold higher risk of dying within a year after receiving a defibrillator.
ACC 2020: VOYAGER PAD Results Add Valuable Knowledge to Field of Peripheral Artery Disease
The DCRI’s Manesh Patel, MD, who was a member of the steering committee for this late-breaking clinical trial, has been working for years to determine the best treatment strategies for patients with peripheral artery disease.
Updated Meta-Analysis Confirms that Patients with Atrial Fibrillation Undergoing PCI Should Avoid Triple Antithrombotic Therapy with Warfarin
Recent evidence suggests that a novel oral anticoagulant plus a P2Y12 inhibitor may be the best treatment pathway for patients with atrial fibrillation undergoing percutaneous coronary intervention. DCRI faculty contributed to a meta-analysis recently published in JAMA Cardiology, which drew data from five clinical trials, including DCRI-led AUGUSTUS, to evaluate the safety and efficacy of four different antithrombotic regimens.
Paper Details Design of ADAPTABLE, First Pragmatic Trial to Use PCORnet®
A paper recently published in JAMA Cardiology details the design of ADAPTABLE, a DCRI-led pragmatic clinical trial that uses many novel elements to efficiently answer a question that has substantial impacts on public health. ADAPTABLE seeks to determine the optimal dose of aspirin for patients with heart disease. Although aspirin has been used as a secondary prevention method for nearly three decades, the question of whether low-dose or high-dose aspirin is more beneficial remains unanswered.
Preventing Alzheimer’s Disease? Taking the First Step Through the TOMMORROW Trial
The study sought to simultaneously test a method for identifying individuals at high risk for Alzheimer’s disease while testing the efficacy of a potential treatment aimed at targets affecting cell
Patient-Reported Health Data in Pragmatic Trials: Helpful, But Not Without Limitations
A report from an NIH Health Care Systems Research Collaboratory roundtable recently published in
12-month SECURE-PCI Results add Context to Original Findings
Although initial results from SECURE-PCI suggested that patients treated with periprocedural loading doses of atorvastatin and undergoing percutaneous coronary intervention (PCI) experienced a reduced risk of major adverse cardiovascular events (MACE), extended follow-up showed no significant difference. The 12-month results, which were recently published in JAMA, expand upon the initial study, which followed patients for 30 days.